Tvardi Therapeutics Ownership
$0.88
4.18%
Nasdaq, Oct 27, 11:49 am EDT.
Market open.
Index
Industry
Tvardi Therapeutics Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Sporos Bioventures LLC
|
837.636k | 8.93% | — | Mar 31 2026 |
| 2 |
Solas Tvardi Sidecar LLC
|
761.287k | 8.12% | — | Mar 31 2026 |
| 3 |
Slate Path Capital LP
|
704.118k | 7.51% | — | Jun 30 2026 |
| 4 |
Tweardy (David John)
|
649.046k | 6.92% | — | Mar 31 2026 |
| 5 |
DePinho (Ronald A)
|
426.190k | 4.54% | -200.000k | Dec 31 2025 |
|
1
Sporos Bioventures LLC
|
8.93%
837.636k
|
|
2
Solas Tvardi Sidecar LLC
|
8.12%
761.287k
|
|
3
Slate Path Capital LP
|
7.51%
704.118k
|
|
4
Tweardy (David John)
|
6.92%
649.046k
|
|
5
DePinho (Ronald A)
|
4.54%
426.190k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 36.02% of Tvardi Therapeutics, with Sporos Bioventures LLC the biggest at 8.93%, followed by Solas Tvardi Sidecar LLC (8.12%) and Slate Path Capital LP (7.51%). |
Recent Tvardi Therapeutics Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 27 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 24 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 20 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 15 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Oct 09 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Oct 02 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 27 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 24 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 20 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 15 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Oct 09 2026
$170.50
|
|
Lisa Park
SALES
|
Oct 02 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Tvardi Therapeutics Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Tvardi Therapeutics has fallen over the past 6 months from around 5.9% to 1.7% of the float. Fewer and fewer market participants are betting on falling prices. That points to easing skepticism, as short sellers increasingly unwind their positions. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
